Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $124.6 million.

  • Regenxbio's Total Current Liabilities rose 2126.36% to $124.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.6 million, marking a year-over-year increase of 2126.36%. This contributed to the annual value of $103.2 million for FY2024, which is 2078.57% down from last year.
  • Per Regenxbio's latest filing, its Total Current Liabilities stood at $124.6 million for Q3 2025, which was up 2126.36% from $119.5 million recorded in Q2 2025.
  • Regenxbio's 5-year Total Current Liabilities high stood at $130.5 million for Q4 2021, and its period low was $84.0 million during Q1 2021.
  • For the 5-year period, Regenxbio's Total Current Liabilities averaged around $113.4 million, with its median value being $114.6 million (2022).
  • In the last 5 years, Regenxbio's Total Current Liabilities soared by 16411.97% in 2021 and then plummeted by 2078.57% in 2024.
  • Quarter analysis of 5 years shows Regenxbio's Total Current Liabilities stood at $130.5 million in 2021, then decreased by 0.03% to $130.4 million in 2022, then fell by 0.12% to $130.3 million in 2023, then fell by 20.79% to $103.2 million in 2024, then rose by 20.71% to $124.6 million in 2025.
  • Its last three reported values are $124.6 million in Q3 2025, $119.5 million for Q2 2025, and $106.7 million during Q1 2025.